Kin MBA - HUTCHMED DRC Senior Communications
| HCM Stock | USD 15.00 0.25 1.64% |
Executive
Kin MBA is Senior Communications of HUTCHMED DRC
| Age | 49 |
| Address | Cheung Kong Center, Hong Kong, Hong Kong |
| Phone | 852 2121 8200 |
| Web | https://www.hutch-med.com |
HUTCHMED DRC Management Efficiency
At this time, HUTCHMED DRC's Return On Tangible Assets are very stable compared to the past year. As of the 1st of February 2026, Return On Assets is likely to grow to 0.04, while Return On Capital Employed is likely to drop (0.05). At this time, HUTCHMED DRC's Fixed Asset Turnover is very stable compared to the past year. As of the 1st of February 2026, Return On Assets is likely to grow to 0.04, while Other Current Assets are likely to drop about 13.2 M. HUTCHMED DRC's management efficiency ratios could be used to measure how well HUTCHMED DRC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| FACC MD | Kiniksa Pharmaceuticals | 59 | |
| Jasgit MD | Ideaya Biosciences | N/A | |
| Ross Moat | Kiniksa Pharmaceuticals | 46 | |
| Chad Morin | Kiniksa Pharmaceuticals | N/A | |
| JD Esq | Ideaya Biosciences | 52 | |
| Alison Ives | Perrigo Company PLC | 44 | |
| Clarice McCauley | Adaptive Biotechnologies Corp | N/A | |
| Minji MBA | Mineralys Therapeutics Common | N/A | |
| Kevin Esq | Supernus Pharmaceuticals | 64 | |
| Erin CPA | Scholar Rock Holding | 51 | |
| Matthew Winterman | Perrigo Company PLC | N/A | |
| Beth Shafer | Scholar Rock Holding | N/A | |
| Arthur Shannon | Bausch Health Companies | N/A | |
| Donald Pearl | Bausch Health Companies | N/A | |
| William Woodfield | Bausch Health Companies | N/A | |
| Martina Struck | Kiniksa Pharmaceuticals | N/A | |
| Jeffrey Fellows | Mineralys Therapeutics Common | N/A | |
| Lisa Wyman | Scholar Rock Holding | N/A | |
| Rushmie Nofsinger | Scholar Rock Holding | N/A | |
| Lisa Price | Scholar Rock Holding | N/A | |
| MBA MD | Supernus Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | 0.47 | ||||
| Return On Asset | -0.0081 |
HUTCHMED DRC Leadership Team
Elected by the shareholders, the HUTCHMED DRC's board of directors comprises two types of representatives: HUTCHMED DRC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED DRC's management team and ensure that shareholders' interests are well served. HUTCHMED DRC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED DRC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kin MBA, Senior Communications | ||
| Thomas Fu, Senior Quality | ||
| CA BEc, CFO Director | ||
| Ming MD, Head VP | ||
| CS CGP, Company Director | ||
| Yiling Cui, Executive Operations | ||
| Charles Nixon, Group Counsel | ||
| Qingmei Wang, Executive Alliances | ||
| BSE CS, Company Director | ||
| Selina Zhang, Senior Resources | ||
| Karen Atkin, Executive COO | ||
| Zhenping MBA, Executive Manufacturing | ||
| David Ng, Head Strategies | ||
| Hong Chen, Executive China | ||
| ACGI BSc, Ex Chairman | ||
| Weiguo BSc, Chief CEO |
HUTCHMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED DRC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.47 | ||||
| Return On Asset | -0.0081 | ||||
| Profit Margin | 0.78 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 1.33 B | ||||
| Shares Outstanding | 171.9 M | ||||
| Shares Owned By Institutions | 3.38 % | ||||
| Number Of Shares Shorted | 332.42 K | ||||
| Price To Earning | 335.94 X | ||||
| Price To Book | 2.12 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HUTCHMED DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Pharmaceuticals sector continue expanding? Could HUTCHMED diversify its offerings? Factors like these will boost the valuation of HUTCHMED DRC. Market participants price HUTCHMED higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every HUTCHMED DRC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 16.333 | Earnings Share 2.65 | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets |
Understanding HUTCHMED DRC requires distinguishing between market price and book value, where the latter reflects HUTCHMED's accounting equity. The concept of intrinsic value—what HUTCHMED DRC's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push HUTCHMED DRC's price substantially above or below its fundamental value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, HUTCHMED DRC's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.